Orally Administered Activated Charcoal as a Medical Countermeasure for Acute Radiation Syndrome in Rats

Featured Application: High porosity activated charcoal can be administered per orally for mitigation of radiation-induced intoxication and intoxication related to different pathological states. Activated charcoal (AC) can be taken orally as enterosorbent for treatment of pathological states related to exogenous and endogenous intoxications. Synthesized granulated AC with a highly developed active surface (S-BET similar to 2700 m(2)/g) was used as a medical countermeasure (MCM) to acute radiation sickness (ARS) in rats after total body X-ray irradiation. AC demonstrates positive results in ARS treatment, as expressed in, (i) a decrease in body weight loss, (ii) a protection of bone marrow (BM) cells colony formation capacity, (iii) a reduction of BM chromosomal aberrations and small intestine and spleen tissue damage, (iv) an amelioration of white blood cell count, and (v) a mitigation of superoxide ion generation rate in the liver. AC oral prescription seems to be perspective modality of ARS treatment.

Automated summary

Activated charcoal administered orally has been shown to be effective in mitigating symptoms of radiation sickness, including weight loss, protection of bone marrow cells, and reduction of chromosomal aberrations.